9/21/2020 7:31:36 AM
MacroGenics Says $15 Mln Milestone Triggered By Initiation Of Phase 3 Trial In NSCLC By Incyte
6/16/2020 7:57:02 AM
MacroGenics Appoints Stephen Eck As SVP, Clinical Development & Chief Medical Officer
6/5/2020 7:36:23 AM
MacroGenics Says FDA Granted Orphan Drug Designation To Margetuximab
5/28/2020 7:38:20 AM
MacroGenics Provides Update On FDA Review Of Margetuximab; Says Advisory Committee Meeting Not Required
5/27/2020 7:36:19 AM
MacroGenics Plans For Clinical Study Intended To Support Registration In US Of Flotetuzumab
4/27/2020 12:44:38 AM
MacroGenics Announces Presentation Of Flotetuzumab Translational Data At 2020 AACR Annual Meeting
7/18/2019 9:07:27 AM
Wedbush Reiterates MacroGenics Inc. (MGNX) At Outperform With $27 Price Target
6/5/2019 8:51:53 AM
Wedbush Reiterates MacroGenics Inc. (MGNX) At Outperform With $27 Up From $26 Price Target
5/16/2019 6:44:44 AM
Wedbush Reiterates MacroGenics Inc. (MGNX) At Outperform With $26 Price Target
5/3/2019 8:39:47 AM
Wedbush Ups MacroGenics Inc. (MGNX) To Outperform From Neutral With $26 Price Target
2/12/2019 11:08:47 PM
MacroGenics Prices Public Offering Of 5.5 Mln Shares At $20/Shr
2/7/2019 8:24:09 AM
Wedbush Cuts MacroGenics Inc. (MGNX) To Neutral From Outperform With $26 Up From $20 Price Target
2/6/2019 6:01:55 AM
MacroGenics Announces Positive Results From Pivotal Phase 3 SOPHIA Study Of Margetuximab
1/22/2019 7:49:39 AM
Wedbush Is Increasing MacroGenics Inc. (MGNX) FY18 Rev. Estimate To 60.3 M From 44.0 M